Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Smith & Nephew    SN.   GB0009223206

SMITH & NEPHEW (SN.)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe Europe - 07/20 05:30:00 pm
1335 GBp   +0.41%
07/18ZIMMER BIOMET : Strategies For The $17 Billion Major Orthopedic Impl..
AQ
07/08SMITH & NEPHEW : Keimig, Hubka
AQ
07/04SMITH & NEPHEW : Timing of Smith & Nephew Second Quarter Trading and..
PU
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/16/2018 07/17/2018 07/18/2018 07/19/2018 07/20/2018 Date
1332(c) 1334(c) 1330(c) 1329.5(c) 1335 Last
1 353 974 2 858 721 2 422 043 2 649 406 1 906 657 Volume
-0.97% +0.15% -0.30% -0.04% +0.41% Change
More quotes
Financials (USD)
Sales 2018 5 009 M
EBIT 2018 1 002 M
Net income 2018 659 M
Debt 2018 1 102 M
Yield 2018 2,06%
Sales 2019 5 189 M
EBIT 2019 1 102 M
Net income 2019 779 M
Debt 2019 823 M
Yield 2019 2,34%
P/E ratio 2018 22,07
P/E ratio 2019 18,84
EV / Sales2018 3,25x
EV / Sales2019 3,09x
Capitalization 15 200 M
More Financials
Company
Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices.It offers the following products and services: sports medicine joint repair; arthroscopic enabling technologies; trauma and extremities; other surgical businesses; knee and hip implants, and advanced... 
More about the company
Surperformance© ratings of Smith & Nephew
Trading Rating : Investor Rating :
More Ratings
Latest news on SMITH & NEPHEW
01:01pToday’s Free Research Reports Coverage on Neovasc and Three More Healthcare S..
AC
07/18ZIMMER BIOMET : Strategies For The $17 Billion Major Orthopedic Implants Market
AQ
07/10SMITH & NEPHEW : LCDCP Plate Hole of Smith & Nephew or Synthes or Zimmer
AQ
07/08SMITH & NEPHEW : Keimig, Hubka
AQ
07/04SMITH & NEPHEW : Timing of Smith & Nephew Second Quarter Trading and First Half ..
PU
06/29SMITH & NEPHEW : Proximal Femoral Locking Plate with Eight Corresponding Locking..
AQ
06/26SMITH & NEPHEW : 'Performance-led Procurement Why innovation should be front and..
AQ
06/25'PERFORMANCE-LED PROCUREMENT : Why innovation should be front and centre' says P..
AQ
06/22SMITH & NEPHEW : UK's NICE publishes a Medtech innovation briefing on PICO for t..
AQ
06/21“PERFORMANCE-LED PROCUREMENT : Why innovation should be front and centre&r..
PU
More news
Sector news : Medical Devices & Implants
07/18Smiths Group medical unit hurt by EU medical devices regulation
RE
07/17BAXTER INTERNATIONAL : Releases FDA Warning Letter for 2017 Inspection in India
DJ
07/11Brazil prosecutors allege jailed GE executive helped company partake in medic..
RE
07/11MEDTRONIC : Gets FDA Approval for Less-Invasive Heart Pump Implant Procedure
DJ
07/09BECTON DICKINSON AND : Completes Acquisition of TVA Medical
DJ
More sector news : Medical Devices & Implants
4-Traders Strategies on SMITH & NEPHEW 
SMITH & NEPHEW  - 2015
Near a major level
SELL
SMITH & NEPHEW PLC - 2013
Lower limit of a trading channel
BUY
More Strategies
Latest Tweets
06/14WPP chairman Roberto Quarta should follow Sir Martin Sorrell out the door  
06/13WPP chairman Roberto Quarta should follow Sir Martin Sorrell out the door  
06/12WPP chairman Roberto Quarta should follow Sir Martin Sorrell out the door
2
06/11Revealed: WPP chairman Roberto Quarta will suffer a more limited revolt, with.. 
06/08WPP Chairman Roberto Quarta said there would be 'no sacred cows' in deciding ..
9
More tweets
Qtime:83
News from SeekingAlpha
07/06Med devices group joins broad rally 
06/11Sell-siders weigh in on possible Boston Scientific - Stryker marriage 
05/29My IMF Portfolio's Top 30 Holdings (Part 1) 
05/14SMITH & NEPHEW : Not Attractive Enough 
05/04Smith & Nephew's (SNN) CEO Olivier Bohuon on Q1 2018 Results - Earnings Call .. 
Chart SMITH & NEPHEW
Duration : Period :
Smith & Nephew Technical Analysis Chart | SN. | GB0009223206 | 4-Traders
Technical analysis trends SMITH & NEPHEW
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 18,7 $
Spread / Average Target 8,0%
EPS Revisions
Managers
NameTitle
Namal Nawana Chief Executive Officer & Executive Director
Roberto Quarta Chairman
Matthew R. Stober President-Global Operations
Graham James Baker Chief Financial Officer & Director
Vasant Padmanabhan President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SMITH & NEPHEW3.22%15 200
STRYKER CORPORATION12.21%64 929
WRIGHT MEDICAL GROUP NV12.84%2 650
JAPAN LIFELINE CO., LTD.21.73%2 317
GLAUKOS CORP63.08%1 481
CERUS CORPORATION120.41%960